News Search Results
Mar 01, 2026, 19:30 ET XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM).- In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma (DLBCL),
More news about: Antengene Corporation Limited
Feb 25, 2026, 08:00 ET Immunexpress Announces Publication Demonstrating SeptiCyte RAPID® Utility for Differentiating Infection from Sterile Inflammation in Readmitted Bone Marrow Transplant Patients with Febrile Neutropaenia
in the European Journal of Haematology, evaluated the performance of SeptiCyte RAPID in patients with acute leukemia, B–cell lymphoma and multiple myeloma after bone marrow stem cell transplantation.Key FindingsElevated SeptiScores® were associated with clinically
More news about: Immunexpress, Inc.
Feb 24, 2026, 08:00 ET K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026
chemotherapy.KTX-2001 is a small molecule, selective inhibitor of nuclear receptor binding SET domain protein 2 (NSD2, also known as multiple myeloma [MM] SET domain-containing protein [MMSET]/Wolf-Hirschhorn syndrome candidate 1 protein [WHSC1]). KTX-2001 inhibits NSD2-mediated dimethylation of
More news about: K36 Therapeutics
Feb 23, 2026, 14:53 ET Sun Life to proactively offer second opinions on cancer diagnoses when members file a cancer-related claim
annual cost of a cancer claim ranged from about $235,000 for malignant neoplasm ("solid" cancers) to over $300,000 for leukemia, lymphoma, and multiple myeloma (blood cancers). While ECR is already available through an employer's Sun Life medical stop-loss policy, members can now receive proactive outreach
More news about: Sun Life U.S.
Feb 19, 2026, 16:01 ET Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate
up period by 6-12 months.*The 12 cancer types include anus, bladder, colorectal, esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas, stomach.About the NHS-Galleri Trial (NCT05611632; ISRCTN91431511)The NHS-Galleri trial
More news about: GRAIL, Inc.
Feb 17, 2026, 16:01 ET HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone ("D-VRd") for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.In December 2025, Halozyme and Skye Bioscience entered into a non-exclusive global
More news about: Halozyme Therapeutics, Inc.
Feb 17, 2026, 11:25 ET /C O R R E C T I O N -- BLOOD CANCER UNITED, INC./
founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers—including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.Blood Cancer United offers free, trustworthy resources, personalized support, and
More news about: BLOOD CANCER UNITED, INC.
Feb 17, 2026, 08:30 ET Accord Healthcare Launches Lenalidomide Capsules, Expanding Access to Essential Oncology Therapies
Lenalidomide is an oral immunomodulatory agent widely used in the treatment of multiple myeloma, mantle cell lymphoma, and non-Hodgkins Lymphoma. The launch of Accord's Lenalidomide Capsules provides increased patient access in a complex oncology
More news about: Accord Healthcare US
Feb 16, 2026, 10:15 ET CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
share of 25.3% in 2025.By target, the CD19 segment is expected to dominate the market, with a share of 62.3%.By indication, multiple myeloma dominated the CAR T- cell therapy market.By demographics, the adult segment is expected to dominate the market.By end user, the hospitals
More news about: MarketsandMarkets
Feb 12, 2026, 17:31 ET BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
indications, such as Myelodysplastic Syndrome, Multiple Myeloma, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Waldenström's Macroglobulinemia, Non-Hodgkin Lymphoma, and others.In 2024, the total incident cases of multiple myeloma in the 7MM were around 76K.Leading BCL-2
More news about: DelveInsight Business Research, LLP
Feb 12, 2026, 07:30 ET Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
(n=117). The trial is being conducted in collaboration with the European Myeloma Network and is evaluating the all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 in their immediate prior line of therapy.Anticipated
More news about: Karyopharm Therapeutics Inc.
Feb 11, 2026, 13:38 ET Black Health Matters Brings Health & Wellness Movement to Atlanta During Black History Month
healthcare professionals and advocates addressing critical topics such as nutrition, kidney disease, heart health, cancer prevention, multiple myeloma, and more.The event will also include engaging, hands-on experiences, including fitness sessions with the "Guru of Abs," DaShaun Johnson,
More news about: Black Health Matters
Feb 05, 2026, 10:59 ET K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO
chemotherapy.KTX-2001 is a small molecule, selective inhibitor of nuclear receptor binding SET domain protein 2 (NSD2, also known as multiple myeloma [MM] SET domain-containing protein [MMSET]/Wolf-Hirschhorn syndrome candidate 1 protein [WHSC1]). KTX-2001 inhibits NSD2-mediated methylation of histone
More news about: K36 Therapeutics
Feb 05, 2026, 07:30 ET Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Feb 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please
More news about: Karyopharm Therapeutics Inc.
Feb 02, 2026, 08:52 ET Quest Diagnostics Launches Novel Flow Cytometry MRD Blood Test for Myeloma, Enabling Ultrasensitive Detection of Residual Disease
residual disease (MRD) in patients with the blood cancer myeloma (also called multiple myeloma). Called Quest Flow Cytometry MRD for Myeloma, the new test provides comparable sensitivity as next-generation sequencing methods in detecting residual myeloma*, but at a fraction of the cost, supporting better care
More news about: Quest Diagnostics
Feb 02, 2026, 04:20 ET IoT in Healthcare Market to Reach US$594.5 Bn by 2035 at 23.85% CAGR | Vantage Market Research
https://www.vantagemarketresearch.com/industry-report/veterinary-regenerative-medicine-market-2153Multiple Myeloma Market is valued at USD 28.42 Billion in 2024 and is projected to reach a value of USD 59.015 Billion by 2035 at a CAGR (Compound Annual Growth Rate)
More news about: Vantage Market Research
Jan 29, 2026, 09:00 ET GIVEBYCRUISING PARTNERS WITH BLOOD CANCER UNITED TO ADVANCE BLOOD CANCER RESEARCH
Cancer United is both thoughtful and deeply personal. In 2023, Kopchinski's wife Kimberly, a three-time cancer survivor, was diagnosed with multiple myeloma. She navigated her blood cancer diagnosis and treatment options with trusted information and support from Blood Cancer United. The Kopchinski family
More news about: BLOOD CANCER UNITED, INC.
Jan 27, 2026, 15:49 ET DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
America, South America, and Europe. About Multiple Myeloma Multiple myeloma is a blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.3 In multiple myeloma, these malignant plasma cells proliferate and replace normal
More news about: Johnson & Johnson
Jan 26, 2026, 19:00 ET Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma
Drug Administration (FDA). This designation applies to the treatment of relapsed or refractory multiple myeloma, (R/R MM) in patients who have received four or more lines of previous anti-myeloma therapies, that include at least a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38
More news about: Innovent Biologics
Jan 21, 2026, 10:00 ET Medlive Expands Advisory Board with Three Leading Oncology Experts
cholangiocarcinoma.Hans Lee, MD, serves as Director of Myeloma Research at Sarah Cannon Research Institute. His clinical and research efforts are focused on advancing the care and treatment of patients with multiple myeloma and other plasma cell dyscrasias. Specifically, Dr. Lee's primary
More news about: Medlive
Jan 14, 2026, 16:30 ET TECVAYLI® monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
www.DARZALEX.com.About Multiple MyelomaMultiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.5 In multiple myeloma, these plasma cells proliferate and spread rapidly and
More news about: Johnson & Johnson
Jan 14, 2026, 09:00 ET High School Students Nationwide Kick off Philanthropic Competition to Help All Blood Cancer Patients Live Longer, Better Lives
founding in 1949, it has consistently evolved to better serve people affected by all 100-plus types of blood cancers—including leukemia, lymphoma, myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms. Blood Cancer United offers free, trustworthy resources, personalized support,
More news about: BLOOD CANCER UNITED, INC.
Jan 13, 2026, 12:33 ET Adimab Records Another Year of Double-Digit Clinical Program Growth
dyslipidemia.IASO Bio's FUCASO® (equecabtagene autoleucel), a BCMA CAR-T program approved in China for the treatment of patients with multiple myeloma.Invivyd's PEMGARDA™ (pemivibart), a SARS-CoV-2 monoclonal antibody authorized for prophylactic emergency use in the United States to prevent
More news about: Adimab, LLC
Jan 13, 2026, 08:15 ET ACS Annual Statistics Report: Milestone 70 Percent 5-Year Survival Rate for all Cancers Combined; Largest Gains for Advanced and Fatal Cancers
during 2015-2021 in the United States. Survival gains since the mid-1990s are especially notable for people diagnosed with more fatal cancers, such as myeloma (from 32% to 62%), liver cancer (7% to 22%), and lung cancer (15% to 28%). These important findings are published today in
More news about: American Cancer Society